Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

Clinical trial NCT01772147 · COMPLETED

Trial details

NCT number: NCT01772147
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Pulmonary Disease, Chronic Obstructive

Start date: 2013-01-01
Primary completion: 2013-08-01
Enrollment: 608

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.